Stroke Biomarker Composition Using Prox1 and Dcx mRNA Thresholds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for diagnosing and predicting stroke and post-stroke neurological damage are inadequate, leading to insufficient understanding of sequelae and long-term disabilities, with existing treatments often failing to address the severity of neurological impairment.
Innovation Solution
Measuring the expression levels of Prox1 and Dcx mRNAs in biological samples and comparing them to control levels to diagnose stroke or post-stroke neurological damage, determining severity, and administering appropriate treatments based on mRNA levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional biomarkers are used for stroke diagnosis, then existing diagnostic methods can be maintained, but the accuracy and ability to predict prognosis and severity are insufficient
Solution Approach 1:
The patent changes the diagnostic parameters from conventional biomarkers to specific mRNA expression levels (Prox1 and Dcx) as quantitative markers. By measuring and comparing mRNA expression levels against established thresholds, the system achieves improved diagnostic accuracy and prognosis prediction capability, directly resolving the contradiction between maintaining conventional methods and achieving superior predictive performance.
2Ease of operation
If existing treatment approaches are used, then current treatment protocols can be followed, but they fail to adequately address the severity of neurological impairment
Solution Approach 1:
The patent introduces dynamic treatment stratification based on mRNA expression levels. Instead of a static treatment protocol, the system dynamically adjusts treatment approaches according to measured Prox1 and Dcx mRNA levels, enabling personalized treatment intensity that matches the severity of neurological impairment. This resolves the contradiction by making treatment effectiveness adaptive rather than fixed.
Solution Approach 2:
The patent establishes a feedback loop where mRNA expression levels are measured, compared against thresholds, and used to guide treatment decisions. This feedback mechanism ensures that treatment intensity is continuously adjusted based on actual neurological status and biomarker data, improving treatment effectiveness while maintaining operational simplicity through automated decision support.
3Measurement precision
If comprehensive biomarker panels are developed, then diagnostic accuracy improves, but the complexity of measurement and analysis increases
Solution Approach 1:
The patent extracts and focuses on only two critical mRNA markers (Prox1 and Dcx) from the complex landscape of potential biomarkers. By isolating and measuring just these two specific markers with established thresholds, the system achieves high diagnostic precision without the complexity of comprehensive multi-marker panels, thus resolving the contradiction between precision and complexity.
Data Source
AI summary
The present invention relates to a biomarker composition for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis, and the like. Using an ischemic stroke mouse disease model, a tissue damage analysis and a behavioral analysis were performed, and the mRNA level expression was confirmed, and as a result, Prox1 or Dcx could be selected as a biomarker. In addition, it was confirmed that the expression of Prox1 or Dcx increased as the severity of stroke or post-stroke neurological damage was higher, and thus the present invention is expected to be useful for diagnosing stroke or post-stroke neurological damage, for diagnosing the severity of stroke or post-stroke neurological damage, and for predicting stroke prognosis.